Cancers Associated with Elevated CA-125 Levels

Primary Gynecological Cancers with Elevated CA-125

Epithelial ovarian cancer is present in approximately 85% of patients with advanced disease, and only elevated in about 50% of early-stage cases, according to the American College of Radiology 1, 2, 3
High-grade serous carcinoma accounts for 70% of epithelial ovarian cancer cases, followed by endometrioid carcinoma (10%), clear cell carcinoma (6-10%), low-grade serous carcinoma (5%), and mucinous carcinoma (3-4%), as reported by the American College of Radiology 4

Non-Gynecological Cancers with Elevated CA-125

Colorectal cancer and breast cancer can have elevated CA-125 levels, as noted by the American College of Radiology 3

Clinical Significance and Limitations

CA-125 is not specific for ovarian cancer and has limited value as a screening test, but aids diagnosis when interpreted alongside imaging and clinical findings, according to the American College of Radiology and the Journal of the American College of Radiology 1, 5
A CA-125/CEA ratio of >25 favors ovarian origin over gastrointestinal origin, as reported by the American College of Radiology 1, 3
Measuring CEA and CA 19-9 in addition to CA-125 helps distinguish primary ovarian tumors from gastrointestinal metastases, according to the American College of Radiology 1, 4

Benign Conditions with Elevated CA-125

Endometriosis, pelvic inflammatory disease, ovarian cysts, and cirrhosis can have elevated CA-125 levels, as noted by the American College of Radiology and the Journal of the American College of Radiology 1, 5, 3

Diagnostic and Monitoring Considerations for Mucinous Ovarian Tumors

Diagnostic Value and Limitations

The European Society of Gynecological Oncology recommends measuring serum carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9) in addition to CA-125 to help distinguish primary mucinous ovarian tumors from gastrointestinal metastases 6, 7
When evaluating mucinous ovarian tumors, endoscopy should be considered if either CEA or CA 19-9 is elevated, especially if the CA-125/CEA ratio is less than 25:1, as suggested by the European Society of Gynecological Oncology 6, 8

Alternative Diagnostic Approaches

Ultrasound-based diagnostic models, such as the IOTA Simple Rules or IOTA ADNEX model, are superior to CA-125 alone in distinguishing between benign and malignant ovarian tumors, according to the International Ovarian Tumor Analysis group 6, 8
False-positive CA-125 elevations can occur with benign conditions, highlighting the importance of considering alternative diagnostic approaches, as noted by the American College of Obstetricians and Gynecologists 6

CA-125 Testing in Ovarian and Endometrial Cancer

Clinical Indications and Limitations

The American College of Obstetricians and Gynecologists recommends CA-125 for monitoring disease response to treatment and detecting recurrence in patients with established epithelial ovarian cancer, with a sensitivity of 62-74% for detecting ovarian cancer recurrence 9
CA-125 should be considered in select endometrial cancer patients with advanced disease, serous histology, or elevated pretreatment levels, accounting for 15% of asymptomatic recurrence detection 9
More than half of patients with advanced-stage or high-grade endometrial cancer have elevated pretreatment CA-125 levels, according to the American College of Obstetricians and Gynecologists 9
Previous radiotherapy may cause elevated CA-125 levels, as noted by the American Journal of Obstetrics and Gynecology 9

CA-125 Elevation: Clinical Interpretation and Management

Introduction to CA-125

Only 50% of stage I ovarian cancers produce elevated CA-125 levels, making it a poor screening tool for early disease, as stated by the Ca-A Cancer Journal for Clinicians 10
Cirrhosis with ascites universally elevates CA-125 because mesothelial cells under pressure from fluid produce the antigen, according to Hepatology 11

Imaging and Risk Assessment

Transvaginal ultrasound with color or power Doppler is the primary imaging modality to evaluate for ovarian masses, with features such as solid components, papillary projections, thick septations, ascites, or complex masses indicating concern for malignancy, as noted in Radiology 12
The American College of Radiology O-RADS US system provides structured risk assessment, with O-RADS 2 indicating <1% malignancy risk, O-RADS 3 indicating 1-10% risk, O-RADS 4 indicating 10-50% risk, and O-RADS 5 indicating ≥50% risk, as described in Radiology 12

Monitoring and Surveillance

Serial CA-125 measurements require two elevated values at least one week apart to confirm progression in established ovarian cancer patients, as stated in Annals of Oncology 13 and Annals of Oncology 14
Rising CA-125 in asymptomatic patients after treatment typically precedes clinical relapse by 2-6 months, according to the Journal of the National Comprehensive Cancer Network 15
The American College of Radiology recommends against using CA-125 alone to make surgical decisions, and advises against testing serum CA-125 in patients with ascites of any cause, as it is universally elevated and nonspecific, as noted in Hepatology 11

Elevated CA-125 in Postmenopausal Women: Diagnostic Approach

Initial Evaluation and Referral

For a 57-year-old postmenopausal woman with elevated CA-125, immediate referral to a gynecologic oncologist is warranted, along with transvaginal ultrasound with color Doppler as the first-line imaging study to evaluate for ovarian malignancy, as recommended by the National Comprehensive Cancer Network 16
The ACOG/SGO criteria specifically recommend referral for postmenopausal women with elevated CA-125, nodular or fixed pelvic mass, metastatic disease or ascites, or family history of breast or ovarian cancer 16

Management of Elevated CA-125 in Ovarian Cancer

Initial Diagnostic Workup

The National Comprehensive Cancer Network recommends follow-up with comprehensive CT scan of chest/abdomen/pelvis, MRI, or PET-CT as clinically indicated for patients with elevated CA-125 17

Context-Specific Management

For Patients with Known Ovarian Cancer History

For patients with rising CA-125 without previous chemotherapy, manage as newly diagnosed disease with appropriate surgical debulking if imaging confirms recurrence, and monitor with pelvic exams every 2-3 cycles, CBC with platelets, chemistry profiles, and CA-125 before each chemotherapy cycle, as recommended by the National Comprehensive Cancer Network 17
The National Comprehensive Cancer Network suggests monitoring with CA-125 before each chemotherapy cycle for patients with known ovarian cancer history 17

Follow-Up Protocol

For Confirmed Ovarian Cancer

The National Comprehensive Cancer Network recommends CA-125 monitoring at each visit if initially elevated, as well as CBC and chemistry profile as clinically indicated 17

CA-125 Clinical Significance and Interpretation

Primary Clinical Applications

The American College of Oncology recommends CA-125 for monitoring disease response to treatment and detecting recurrence in patients with confirmed epithelial ovarian cancer, particularly high-grade serous carcinoma where it is most reliable 18
The European Society of Medical Oncology suggests that CA-125 criteria for response and progression (GCIG criteria) have utility in routine practice but must be combined with radiological and clinical assessment—never use CA-125 alone for treatment decisions 18, 19
The American College of Oncology states that CA-125 is NOT a reliable marker in non-high-grade serous ovarian cancers, particularly mucinous carcinoma, clear cell, endometrioid, and low-grade serous types 18, 19
The National Comprehensive Cancer Network recommends that the role of CA-125 in assessing response to targeted therapies (including bevacizumab and PARP inhibitors) is not proven; use radiological and clinical assessment instead 18

Screening and Risk Assessment

The National Comprehensive Cancer Network recommends that routine CA-125 screening is NOT recommended for the general population—randomized data do not support this approach 20
The Society of Gynecologic Oncology suggests that CA-125 alone has insufficient sensitivity (only 50% of stage I ovarian cancers have elevated levels) and specificity for screening 20
The American College of Obstetricians and Gynecologists states that for women with BRCA mutations or strong family history, some clinicians monitor with CA-125 and transvaginal ultrasound, though prospective validation remains elusive 20
The National Comprehensive Cancer Network recommends that the ROCA algorithm (using age and longitudinal CA-125 changes) may have utility in high-risk women but is not validated for average-risk screening 20
The Society of Gynecologic Oncology suggests that the OVA1 test should NOT be used as a screening tool per SGO and FDA guidance 20

CA-125 Measurement and Interpretation

Benign Causes of CA-125 Elevation

The American College of Radiology and American Journal of Transplantation document that CA-125 can be abnormally elevated in numerous benign conditions, including hepatitis and renal failure, and heart failure, in patients with chronic diseases 21
Renal failure is a condition that can cause an elevation in CA-125 levels, as documented by the American Journal of Transplantation 21

Evidence‑Based Work‑up for Elevated CA‑125 in Patients with a Family History of Colorectal Cancer

Tumor‑Marker Evaluation

Measure carcinoembryonic antigen (CEA) and CA 19‑9 together with CA‑125 to help differentiate primary ovarian tumors from gastrointestinal (GI) metastases. 22
A CA‑125/CEA ratio < 25:1 should raise suspicion for a GI primary, especially when there is a family history of colorectal cancer. 22

Imaging Strategies

Transvaginal ultrasound with color or power Doppler remains the first‑line modality for characterizing ovarian masses, but ultrasound‑based models (IOTA Simple Rules or IOTA ADNEX) outperform CA‑125 alone in distinguishing benign from malignant lesions. 22
Contrast‑enhanced CT of the thorax, abdomen, and pelvis is essential for staging, surgical planning, and for detecting primary colorectal lesions or hepatic metastases. 22

Endoscopic Evaluation

If CEA or CA 19‑9 is elevated, or if the CA‑125/CEA ratio is < 25:1, colonoscopy and upper endoscopy should be performed to exclude a GI primary tumor. 22

Limitations of CA‑125

CA‑125 is elevated in only about 50 % of early‑stage (FIGO I) ovarian cancers, limiting its utility as a screening test. 22
CA‑125 lacks specificity and can be raised in many benign conditions, including endometriosis, ovarian cysts, pelvic inflammatory disease, cirrhosis, heart failure, and renal failure. 22

Pathologic Confirmation

Definitive diagnosis requires histopathologic examination of adequate tumor tissue obtained via biopsy or surgical specimen. 22
When neoadjuvant chemotherapy is contemplated, sufficient tissue must be collected to allow for molecular (genetic) tumor testing. 22

Genetic Considerations

If ovarian cancer is confirmed, screening for Lynch syndrome is advisable because mismatch‑repair gene mutations confer a 10‑12 % lifetime risk of ovarian cancer (typically endometrioid or clear‑cell subtypes). 22
BRCA1/2 testing is less pertinent unless there is also a family history of ovarian or breast cancer, as these mutations are primarily linked to high‑grade serous ovarian cancer. 22

Management of Fallopian Tube and Primary Peritoneal Cancer

NCCN Guideline Recommendations

The National Comprehensive Cancer Network (NCCN) recommends that fallopian tube cancer and primary peritoneal cancer be managed in the same manner as epithelial ovarian cancer, and that these malignancies demonstrate comparable patterns of CA‑125 elevation. 23